Belite Bio, Inc Belite Bio, Inc

Belite Bio, Inc

BLTE

Kedudukan dalam Saham #3049
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Harga Saham
$148.24
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$5.97B
Perubahan (1 hari)
3.82%
Perubahan (1 tahun)
64.04%
Negara
US
Perdagangan Belite Bio, Inc (BLTE)

Kategori

Healthcare
Bilangan saham terbitan bagi Belite Bio, Inc (BLTE)
Bilangan saham terbitan setakat June 2026: 40.18M
Menurut laporan kewangan terkini dan harga saham Belite Bio, Inc, bilangan saham terbitan semasa ialah 40.18M. Pada akhir December 2023, syarikat mempunyai 26.59M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Belite Bio, Inc (BLTE) dari 2020 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
2026 (TTM) 40.18M 31.58%
2024 30.54M 14.84%
2023 26.59M 33.12%
2022 19.98M -17.09%
2021 24.10M 161.73%
2020 9.21M 0.00%
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
253.90M 531.87%
US
396.00M 885.51%
US
478.91M 1,091.85%
AU
- -
CH
62.19M 54.76%
NL